AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31970564 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM therapy with a CW GaAIAs diode laser (808 nm; 0.028 mm2; 0.1 W; 3.6 W/cm2; 89 J/cm2; 2.5 J/point)
Number of subjects: 20
Study 31970564 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20
Study 30961357 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 29021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment arm (n=30)
Number of subjects: 54
Study 29021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endovascular treatment of the extracranial disease (n=17)
Number of subjects: 54
Study 29021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged carotid revascularization (n=4)
Number of subjects: 54
Study 29021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pseudo-occlusions (n=4)
Number of subjects: 54
Study 29021311 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic agents after acute carotid artery stenting
Number of subjects: 54
Study 29021311 — intervention group
Group type: COMPARATOR
Intervention: Subjects with tandem occlusions
Number of subjects: 54
Study 27418545 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine
Number of subjects: 15
Study 27418545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 15
Study 23722870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogenetics training (4-hour session covering consultation skills, attitude, and clinical knowledge)
Number of subjects: 88
Study 23722870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncogenetics training
Number of subjects: 88
Study 22847178 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA + LC n-3 PUFA
Number of subjects: 59
Study 22847178 — intervention group
Group type: COMPARATOR
Intervention: SFA alone
Number of subjects: 59
Study 19860512 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical maxillary expansion (n = 64)
Number of subjects: 198
Study 19860512 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol without presurgical maxillary expansion
Number of subjects: 198
Study 19860512 — intervention group
Group type: COMPARATOR
Intervention: Patients treated by the highest volume operator
Number of subjects: 198
Study 19860512 — intervention group
Group type: COMPARATOR
Intervention: Patients under 11 years of age
Number of subjects: 198
Study 19860512 — intervention group
Group type: COMPARATOR
Intervention: Unilateral cleft lip and palate patients
Number of subjects: 198
Study 17094088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarizotan 2 mg/day
Number of subjects: 398
Study 17094088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarizotan 10 mg/day
Number of subjects: 398
Study 17094088 — intervention group
Group type: COMPARATOR
Intervention: Sarizotan (2, 4, or 10 mg/day)
Number of subjects: 398
Study 15733882 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-g oral dose of secnidazole (n=44)
Number of subjects: 80
Study 15733882 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-g oral dose of secnidazole (n=32)
Number of subjects: 80
Study 15733882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of secnidazole
Number of subjects: 80
Study 11315503 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm oil (90 mg beta-carotene)
Number of subjects: 86
Study 11315503 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplements
Number of subjects: 86
Study 11315503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 9252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emollient 0.05 percent, 0.43 to 0.5 gm twice daily for four weeks
Number of subjects: 47
Study 9252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emollient 0.05 percent
Number of subjects: 47
Study 9252738 — intervention group
Group type: COMPARATOR
Intervention: Emollient vehicle
Number of subjects: 47
Study 9252738 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate emollient, 1.5 gm applied twice daily for seven consecutive days
Number of subjects: 47
Study 8359085 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 50
Study 8359085 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 50
Study 8359085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2891235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia induced between 3.00 and 4.00 h
Number of subjects: 7
Study 2891235 — intervention group
Group type: COMPARATOR
Intervention: No hypoglycaemia
Number of subjects: 7
Study 30220621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser groove treatment (100μm-deep, 150μm-deep, 200μm-deep)
Number of subjects: 230
Study 30220621 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 230
Study 30220621 — intervention group
Group type: COMPARATOR
Intervention: Air abrasion treatment
Number of subjects: 230
Study 28150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing 180 mg ticagrelor
Number of subjects: 50
Study 28150850 — intervention group
Group type: COMPARATOR
Intervention: Standard oral 180 mg ticagrelor
Number of subjects: 50
Study 28150850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 26521576 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 40
Study 26521576 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 40
Study 24222836 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide infusion <10 hours
Number of subjects: 3271
Study 24222836 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide infusion 10-17 hours
Number of subjects: 3271
Study 24222836 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide per-protocol infusion (18-24 hours)
Number of subjects: 3271
Study 22186753 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% hydrogen peroxide + sodium perborate paste (HP + SP)
Number of subjects: 20
Study 22186753 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% carbamide peroxide + sodium perborate paste (CP + SP)
Number of subjects: 20
Study 19801812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic technique (NDT)
Number of subjects: 40
Study 19801812 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 40
Study 16440115 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin-based regimen
Number of subjects: 20
Study 16440115 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin-based regimen
Number of subjects: 20
Study 16440115 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 15258349 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100-325 mg/d)
Number of subjects: 823
Study 15258349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/d)
Number of subjects: 823
Study 15258349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 823
Study 11419768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes recall system established at eight of the 21 sites, staff training in basic diabetes care, regular phone calls from the project officer, a two‐monthly newsletter and a mid‐project workshop.
Number of subjects: 678
Study 11419768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes recall system established at eight of the 21 sites.
Number of subjects: 678
Study 9438089 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline containing a low dose of epinephrine (50 ml, diluted to 1:200,000) with drain clamping for 20 hours
Number of subjects: 283
Study 9438089 — intervention group
Group type: COMPARATOR
Intervention: Saline only (50 ml) with drain clamping for 20 hours
Number of subjects: 283
Study 9438089 — intervention group
Group type: COMPARATOR
Intervention: No drain-clamp method
Number of subjects: 283
Study 8503807 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study 8503807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3435365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400mg tablet at the first sign of pain or bleeding, followed by 400mg every 4 to 6 hours for the duration of expected symptoms
Number of subjects: 38
Study 3435365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 28763401 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (L)
Number of subjects: 45
Study 28763401 — intervention group
Group type: EXPERIMENTAL
Intervention: Estriol (E)
Number of subjects: 45
Study 28763401 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + Estriol (LE)
Number of subjects: 45
Study 26018670 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 52
Study 26018670 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-Fentanyl
Number of subjects: 52
Study 26200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 180
Study 26200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 180
Study 26200403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 180
Study 26200403 — intervention group
Group type: COMPARATOR
Intervention: Control (Enoxaparin Monotherapy)
Number of subjects: 180
Study 23306362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype vaccine containing LCTBA and CFA/I overexpressing E. coli
Number of subjects: 60
Study 23306362 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype vaccine (higher dose)
Number of subjects: 60
Study 23306362 — intervention group
Group type: COMPARATOR
Intervention: Reference vaccine (CTB and inactivated wild type ETEC bacteria expressing CFA/I)
Number of subjects: 60
Study 21688030 — intervention group
Group type: EXPERIMENTAL
Intervention: HHD group (4% succinylated gelatin infused at 20 ml•kg(‐1)BW•h(‐1) with targeted hematocrit of 30)
Number of subjects: 16
Study 21688030 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional fluid replacement protocol)
Number of subjects: 16
Study 17900579 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone
Number of subjects: 90
Study 17900579 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 90
Study 17900579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16615978 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% povidone-iodine eyedrops
Number of subjects: 0
Study 16615978 — intervention group
Group type: COMPARATOR
Intervention: 1% silver nitrate
Number of subjects: 0
Study 12640221 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 mg/day, increased up to 2.0 mg/day based on response)
Number of subjects: 15
Study 12640221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10702163 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-fat (VLF) diet (10% of energy from fat; 3% from saturated fat)
Number of subjects: 62
Study 10702163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-unsaturated-fat (HUF) diet (32% of energy from fat; 6% from saturated fat)
Number of subjects: 62
Study 10702163 — intervention group
Group type: COMPARATOR
Intervention: High-saturated-fat (HSF) diet (32% of energy from fat; 17% from saturated fat)
Number of subjects: 62
Study 10702163 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets combined
Number of subjects: 62
Study 10702163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diets (HSF and HUF)
Number of subjects: 62
Study 7862905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 22)
Number of subjects: 73
Study 7862905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine (n = 18)
Number of subjects: 73
Study 7862905 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 73
Study 2690098 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-acetylcarnitine
Number of subjects: 130
Study 2690098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 1233188 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot heparin (Calciparin)
Number of subjects: 65
Study 1233188 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 65
Study 28746244 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicycling course (12 sessions)
Number of subjects: 20
Study 31077214 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (group A)
Number of subjects: 130
Study 31077214 — intervention group
Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 130
Study 25269569 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE programme (30 minutes, five times per week for eight weeks, with hot-packs and transcutaneous electrical nerve stimulation)
Number of subjects: 53
Study 25269569 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE programme
Number of subjects: 53
Study 25269569 — intervention group
Group type: COMPARATOR
Intervention: Control group (hot-packs and transcutaneous electrical nerve stimulation)
Number of subjects: 53
Study 25458561 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclazuril (1mg/kg BW)
Number of subjects: 199
Study 25458561 — intervention group
Group type: EXPERIMENTAL
Intervention: Toltrazuril (15mg/kg BW)
Number of subjects: 199
Study 25458561 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 199
Study 22494866 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with Postconditioning (PC)
Number of subjects: 78
Study 22494866 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPCI
Number of subjects: 78
Study 22494866 — intervention group
Group type: EXPERIMENTAL
Intervention: PPCI with Postconditioning (PC) after exclusion of diabetics
Number of subjects: 78
Study 19398001 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD25 mAb induction (daclizumab)
Number of subjects: 15
Study 19398001 — intervention group
Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 15
Study 17880476 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol to maintain nasoenteral tube (NET) patency
Number of subjects: 60
Study 17880476 — intervention group
Group type: COMPARATOR
Intervention: Historical control (baseline data)
Number of subjects: 60
Study 15105387 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) in combination with a paracervical block (PCB) (n = 100)
Number of subjects: 200
Study 15105387 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical analgesia (CMA) in combination with a PCB (n = 100)
Number of subjects: 200
Study 15105387 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 200
Study 15105387 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical analgesia (CMA)
Number of subjects: 200
Study 11706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet search using the search strategy 'study methodology NEAR intervention NEAR condition' on AltaVista
Number of subjects: 429
Study 11706930 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet search for published studies
Number of subjects: 429
Study 9642019 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 2
Study 9642019 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 2
Study 7717792 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured sleep hygiene with early morning light therapy
Number of subjects: 30
Study 7717792 — intervention group
Group type: COMPARATOR
Intervention: Structured sleep hygiene
Number of subjects: 30
Study 7717792 — intervention group
Group type: COMPARATOR
Intervention: Structured sleep hygiene with late afternoon moderate exercise
Number of subjects: 30
Study 1781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic agents (ioxaglate, iohexol)
Number of subjects: 100
Study 1781822 — intervention group
Group type: COMPARATOR
Intervention: Ionic agent (Renografin‐76)
Number of subjects: 100
Study 1781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 100
Study 1781822 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 100
Study 7293938 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (for 10 months)
Number of subjects: 82
Study 7293938 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (for 6 months)
Number of subjects: 82
Study 7293938 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B2)
Number of subjects: 82
Study 30513395 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI-Neurofeedback of right inferior frontal cortex (rIFC)
Number of subjects: 18
Study 29061627 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations and the use of the Jourvie Research app
Number of subjects: 30
Study 29061627 — intervention group
Group type: COMPARATOR
Intervention: Consultations only
Number of subjects: 30
Study 26510725 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily
Number of subjects: 120
Study 26510725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 26510725 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 120
Study 24153331 — intervention group
Group type: COMPARATOR
Intervention: Intervention (not specified in detail, but implied to be treatment for JCCP)
Number of subjects: 0
Study 21425274 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound (CDUS)
Number of subjects: 29
Study 21425274 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomographic Angiography (CTA)
Number of subjects: 29
Study 21425274 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of aneurysm diameter measurement
Number of subjects: 29
Study 19641980 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.6 microg x kg(‐1) and midazolam 9 microg x kg(‐1) premedication (Group FM)
Number of subjects: 80
Study 19641980 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (Group PLAC)
Number of subjects: 80
Study 17823740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler (OD)
Number of subjects: 10
Study 17823740 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 10
Study 15234049 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-irradiation (beta-RT) with (90)Sr, delivered 2500 cGy to the sclera surface at a dose rate of 200-250 cGy/min
Number of subjects: 91
Study 15234049 — intervention group
Group type: COMPARATOR
Intervention: Sham RT (control group), using the same type of applicator without the (90)Sr layer
Number of subjects: 91
Study 11548898 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sinusitis group (patients undergoing transnasal sinus operation)
Number of subjects: 0
Study 11548898 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients undergoing septoplasty)
Number of subjects: 0
Study 11548898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 11398306 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms misoprostol
Number of subjects: 8
Study 11398306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8283895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion pressure of 50 mm Hg
Number of subjects: 60
Study 8283895 — intervention group
Group type: COMPARATOR
Intervention: Reperfusion pressure of 75 mm Hg
Number of subjects: 60
Study 8283895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (50 mm Hg and 75 mm Hg)
Number of subjects: 60
Study 2902671 — intervention group
Group type: EXPERIMENTAL
Intervention: broxaterol (0.5 mg)
Number of subjects: 12
Study 2902671 — intervention group
Group type: EXPERIMENTAL
Intervention: procaterol (0.05 mg)
Number of subjects: 12
Study 2902671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31190608 — intervention group
Group type: EXPERIMENTAL
Intervention: three-stage venous cannula (3S)
Number of subjects: 48
Study 31190608 — intervention group
Group type: EXPERIMENTAL
Intervention: three-stage venous cannula with additional 'fenestrated' ridges (F3S)
Number of subjects: 48
Study 31190608 — intervention group
Group type: COMPARATOR
Intervention: conventional two-stage (2S)
Number of subjects: 48
Study 31190608 — intervention group
Group type: EXPERIMENTAL
Intervention: three-stage cannula (3S)
Number of subjects: 48
Study 28393317 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 52
Study 28393317 — intervention group
Group type: COMPARATOR
Intervention: MS medication video (attention control)
Number of subjects: 52
Study 26224613 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous conditioned plasma (ACP) injections
Number of subjects: 99
Study 26224613 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone injections
Number of subjects: 99
Study 21812820 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 × 8 min training
Number of subjects: 35
Study 21812820 — intervention group
Group type: COMPARATOR
Intervention: Low only (n=8)
Number of subjects: 35
Study 21812820 — intervention group
Group type: COMPARATOR
Intervention: 4 × 16 min
Number of subjects: 35
Study 21812820 — intervention group
Group type: COMPARATOR
Intervention: 4 × 4 min
Number of subjects: 35
Study 21402616 — intervention group
Group type: EXPERIMENTAL
Intervention: lesogaberan (65 mg twice daily)
Number of subjects: 244
Study 21402616 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244
Study 21402616 — intervention group
Group type: EXPERIMENTAL
Intervention: lesogaberan
Number of subjects: 244
Study 18504447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa (HF, 902 mg flavanols)
Number of subjects: 49
Study 18504447 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise (3 x 45 min per week at 75% of age-predicted maximum heart rate)
Number of subjects: 49
Study 18504447 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol cocoa (LF, 36 mg flavanols)
Number of subjects: 49
Study 17038680 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 45 mg total dose (15 mg/day)
Number of subjects: 210
Study 17038680 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine 105 mg total dose (15 mg/day)
Number of subjects: 210